While the low number of events of cholangiocarcinoma in clinical trials precludes informative analyses [9,10,11,12,13,14], this safety signal is currently being monitored by the European Medicines Agency [15, 16]
Primary carnitine deficiency can bring symptoms in infancy while secondary deficiency can occur at all ages according to the factors that are causing it
The injection route also presents practical challenges
Patients concerned about regulatory compliance
The cross-sectional design is a natural limitation making it impossible to determine causal relationships when evaluating the associations
The information provided in this blog is for informational purposes only and should not be taken as an endorsement or recommendation by UK Peptides.